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Phage Capsids as Gated,  
Long-Persistence, Uniform Drug 
Delivery Vehicles
Philip Serwer, Elena T. Wright and Cara B. Gonzales
Abstract
Over the last 25 years, cancer therapies have improved survivorship. Yet, 
metastatic cancers remain deadly. Therapies are limited by inadequate target-
ing. Our goal is to develop a new drug delivery vehicle (DDV)-based strategy 
that improves targeting of drug delivery to solid tumors. We begin with a capsid 
nanoparticle derived from bacteriophage (phage) T3, a phage that naturally has 
high persistence in murine blood. This capsid has gating capacity. For rapidly 
detecting loading in this capsid, here, we describe procedures of native agarose 
gel electrophoresis, coupled with fluorescence-based detection of loaded mol-
ecules. We observe the loading of two fluorescent compounds: the dye, GelStar, 
and the anticancer drug, bleomycin. The optimal emission filters were found 
to be orange and green, respectively. The results constitute a first milestone in 
developing a drug-loaded DDV that does not leak when in blood, but unloads its 
cargo when in a tumor.
Keywords: agarose gel electrophoresis, bacteriophage T3, bleomycin,  
buoyant density centrifugation, capsid impermeability, GelStar
1. Introduction
Current therapies for cancerous tumors suffer from both toxic secondary effects 
and the development by the tumor of drug resistance. These effects usually block 
therapy for metastatic cancers, the cause of 90% of cancer deaths [1–5]. For solving 
these problems, our first thesis is that the best strategy is to increase tumor specific-
ity of anticancer drug delivery in several, independent stages. If, for example, three 
stages are used and each stage is 80% efficient (20% nonefficient) in increasing 
specificity, then overall efficiency is 99% [100 × (1.0 − 0.23)]. In this case, (1) drug 
dosages to tumors can be raised 100× without changing toxicity and, therefore,  
(2) tumor cell evolution of drug resistance is minimized.
The primary alternative is to continue testing chemotherapies [6–8], immuno-
therapies [9–11] and radiotherapies [12–14] that have tumor-specificity determined 
at one independent stage. This one stage is often cellular DNA replication, which is 
more rapid and, therefore, more drug- and radiation-sensitive, in cancerous cells 
than it is in healthy cells. One-stage strategies are >100 years old for immunother-
apy and radiotherapy. Chemotherapeutic agents typically used are over 50 years old 
[8]. Even major effort has not produced systematic therapies for metastatic cancer. 
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Apparently, new, possibly more biology-based, strategy is needed to counter risk 
that the above one-stage-based strategies, in general, are not realistic for reaching 
objectives (reviewed in [1, 15–17]).
In theory, one implementation of multi-stage strategy starts with drug delivery 
in a drug delivery vehicle (DDV) that is gated. The gate is opened to load drug, 
closed in circulation to deliver drug and opened again in tumors to administer drug. 
Stages of DDV-derived toxicity reduction are the following tumor-specific events: 
(1) DDV delivery, (2) DDV opening and, (3) drug activation, for masked drugs. We 
address stages (1) and (2) here.
In this implementation, tumor-specific delivery is achieved via the EPR effect. 
The EPR effect is the spontaneous accumulation of nanoparticles in tumors, 
observed for an uncharacterized phage in 1940 [18] (reviewed in [19]). The causes 
of the EPR effect are (1) porosity of tumor blood vessels and relative tightness of 
healthy blood vessels, so that nanoparticles enter tumors, but usually not healthy 
tissue and (2) poor tumor lymphatic drainage, so that nanoparticles remain  
[20–25]. The EPR effect is the basis for the use of several FDA-approved, drug-
loaded, liposomal DDVs [23, 24, 26].
However, circulating, drug-loaded, liposomal DDVs undergo drug leakage 
that causes significant toxicity [22, 23, 25, 27]. Also, liposomes are removed from 
circulation by the macrophage-phagocyte innate immune system. That is to say, 
liposomes are not very persistent. Chemical solutions to the leakage problem do 
not exist to our knowledge. Chemical solutions to the persistence problem (e.g., 
polyethylene glycol derivatization [28, 29]) introduce quality control problems 
and are not adaptable to future improvements, for example, achieving of tumor-
specific unloading. The second thesis is that the optimal solution is linked to 
finding an appropriate, biologically produced, microbial DDV. Unlike some 
biology-based anticancer strategies [1, 15, 16, 19], use of a DDV is implementable 
with nononcolytic viruses and, therefore, avoids the dangers [19] of using onco-
lytic viruses.
In practice, we have discovered a phage T3 capsid that appears to have DDV-
favorable characteristics needed for implementation of our strategy. First, phage 
T3 (and presumably its capsid) has recently been found to have exceptionally high 
persistence in mouse blood (3–4 h), unlike the T3 relative, T7 [30]. Second, one 
empty, but otherwise phage-like T3 capsid, is impermeable (for over 20 years) 
to the compound, Nycodenz (821 Da molecular weight) (reviewed in [31]). But, 
when the temperature is raised to 45°C, Nycodenz enters this capsid [32], presum-
ably through a gate that opened. The concept is that, if we adapt this capsid to use 
as gated DDV, some of the needed engineering has already been done by natural 
selection.
Phages T3 and T7 are illustrated at the left in Figure 1. The gated capsid is illus-
trated at the right in Figure 1. This capsid is generated during DNA packaging that 
had been initiated by a DNA-free procapsid called capsid I (not shown). During 
packaging, capsid I expands and becomes the more angular and stable capsid (cap-
sid II) illustrated in Figure 1. In nature, the capsid-gate is a ring of 12 gp8 molecules 
(Figure 1) that acts as entry portal for DNA during DNA packaging [31–33]. Most 
T3 and T7 capsid II particles are purified after having detached from DNA during 
infected cell lysis. The amount is 5–10 mg capsid II per liter of culture. The last 
purification step is buoyant density centrifugation in a Nycodenz or Metrizamide 
density gradient. Nycodenz low density (NLD) capsid II has the gp8 “gate” and is 
impermeable to Nycodenz and Metrizamide. The low density (1.08 g/ml) is caused 
by high internal hydration, which is caused by Nycodenz impermeability.  
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Nycodenz high density (NHD) capsid II is Nycodenz-permeable (1.28 g/ml) and is 
completely separated from NLD capsid II during buoyant density centrifugation in 
a Nycodenz or Metrizamide density gradient [31, 33–35]. We use NHD capsid II as a 
control during loading experiments.
In the case of T3 NLD capsid II, gated entry of Nycodenz has been observed via 
raising of temperature. The likely entry channel was the axial hole of the gp8 ring. 
This conclusion was drawn, in the case of T7 NLD capsid II, from (1) entry kinet-
ics of the fluorescent dye, bis-ANS [1,1′-bi(4-anilino)naphthalene-5,5′-di-sulfonic 
acid; 673 Da], and (2) covalent cross-linking of bis-ANS to channel proteins [33]. 
Asymmetric reconstruction-cryo-EM [36] revealed that obstruction of the T7 gp8 
channel (and presumably the T3 channel) varies.
In support of working to implement the above gating-based strategy, the fol-
lowing quote from 2005 presents an expert opinion of what is needed for the next 
generation of anticancer DDVs [27]. “An ideal liposomal anticancer drug would 
exhibit little or no drug release while in the plasma compartment, thus ensuring 
limited exposure of the drug to healthy tissue. This feature would also maximize 
drug delivery to disease sites, as mediated by the movement of the drug-loaded 
liposomes from the plasma compartment to the extravascular space at disease sites, 
such as a region of tumor growth. Following localization, however, the drug-loaded 
liposome must transform itself from a stable carrier to an unstable carrier. This 
would ensure that the drug, which has localized in the diseased site, is bioavailable.” 
To our knowledge, no details for such “controlled release” via a liposomal DDV 
have been published. The system described here is designed to accomplish what is 
described in the above quote. However, implementation uses gating of a DDV, not 
programmed instability of a DDV.
To proceed further, we need a procedure for rapidly determining whether a drug 
is loaded in a capsid. In the current study, we have developed native agarose gel 
electrophoresis (AGE) for this purpose. The detection is performed via capsid band 
fluorescence produced by the compound loaded.
Figure 1. 
Phages T3 and T7 (left); and T3 and T7 NLD capsid II (right). The graphic legend at the top indicates the 
various capsid components. A protein is labeled by gp, followed by the number of the encoding gene. Analogous 
T3 and T7 genes have the same numbers. If NLD capsid II is used as DDV, the perimeter of the DDV is defined 
by the gp10 shell; the gate is the gp8 portal. All structures are the same for phage T3 as they are for phage T7 
(reviewed in [31, 32]).
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2. Results
2.1 Detection of test compounds: GelStar
We tested the loading of two fluorescent compounds. The first was GelStar, a fluo-
rescent nucleic acid stain typically used after AGE. In contrast, we incubated GelStar 
with our capsid and then performed AGE without further use of GelStar. The second 
compound was bleomycin, an anticancer drug [37, 38] that is also fluorescent [38]. 
Neither the manufacturer nor the vendor provided either the structure of GelStar or 
the concentration of commercial GelStar solutions. GelStar is sold in solution only.
The dominant fluorescence emission of nucleic acid-bound GelStar is in the 
green range. Apparently not previously documented is that the dominant fluores-
cence emission of free GelStar is in the orange range, at least when the GelStar is in 
an agarose gel. Ultraviolet light stimulated GelStar fluorescence emission vs. GelStar 
dilution is shown in Figure 2. Free GelStar, at several dilutions, had been pipetted 
in 5 μl amounts onto an agarose gel before ultraviolet light illumination and photog-
raphy through an orange filter (spots labeled G in Figure 2). The effective volume 
in μl (dilution, multiplied by 5) of the stock GelStar solution is also indicated. In 
Figure 2, the color of GelStar spots is orange for all dilutions, as it also is found to 
be (not shown) with yellow and green emission filters. The orange color is real and 
is not produced by the emission filter because green Alexa 488 dye fluorescence 
retains its green color (spots labeled A in Figure 2). The number next to the Alexa 
488 spots is the total amount (μg) of Alexa 488, also applied in 5 μl amounts.
DNA-bound GelStar had the expected green emission at all dilutions, when 
viewed through the same orange emission filter used for Figure 2 (right side of the 
right panel of Figure 3). Green emission was also dominant when yellow and green 
emission filters were used for DNA-bound GelStar (not shown).
2.2 Detection of test compounds: bleomycin
Without fluorescent compound, the background of an agarose gel was blue 
when emission was photographed without an emission filter (not shown). Thus, not 
surprising was that optimal detection of bleomycin was not obtained with a blue 
filter, even though the blue range was where peak emission was previously found 
for bleomycin [38]. Among the blue, green, yellow and orange filters, optimal 
detection was obtained with the green filter.
Figure 2. 
Fluorescence of free GelStar. GelStar and Alexa Fluor 488 were diluted and, then, pipetted onto the surface of 
an agarose gel. The fluorescence was photographed through the orange filter. The GelStar samples are indicated 
by G, followed by the effective volume (μl) of the original, undiluted GelStar solution. The Alexa Fluor 488 
samples are indicated by A, followed by the amount (μg) of Alexa Fluor 488.
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With the green emission filter, the minimal detected bleomycin amount was 
0.2–0.4 ng when a bleomycin dilution series like the GelStar dilution series in 
Figure 2 was photographed (not shown). Contrast enhancement of images was 
used at these lower amounts.
2.3 Loading of GelStar in NLD capsid II
We succeeded in loading GelStar into NLD capsid II. To achieve loading, 10 μg 
of NLD capsid II was incubated with GelStar at 45°C. Loading was then assayed 
by AGE at 10°C. Then, the gel was illuminated with ultraviolet light. The result 
was a fluorescent band of intensity that monotonically increased with decreasing 
GelStar dilution (left section of the right panel of Figure 3). The capsid amount was 
invariant, as judged by Coomassie staining of the same gel (left panel of Figure 3). 
At GelStar dilutions lower than those in Figure 3, down to 1/10, the band intensity 
reached a plateau (not shown). The dominant fluorescence, at all dilutions, was 
green, implying that the GelStar was bound to something capsid associated. GelStar 
did not detectably associate with NHD capsid II (not shown).
The following data indicated that the GelStar-binding capsid site was not on a 
DNA molecule associated with the capsid. As the dilution of GelStar decreased, the 
DNA-bound GelStar fluorescence underwent, first, an increase and then a decrease 
(Figure 3, right segment of right panel). However, the decrease was not observed 
for the binding to NLD capsid II. Second, although a minor NLD capsid II frac-
tion has DNA [31], the DNA-containing NLD capsid II had been excluded during 
purification by selecting the low-density side of the NLD capsid II band after 
buoyant density centrifugation in a Nycodenz density gradient. Thus, the GelStar 
was apparently either self-bound or bound to capsid protein.
2.4 Loading of bleomycin in NLD capsid II
Association of bleomycin with T3 NLD capsid II was also achieved. However, 
the fluorescence signal was relatively weak (Figure 4). The bleomycin fluorescence 
signal of a NLD capsid II band did not change when the concentration of bleomycin 
was changed from 2 to 16 mg/ml. A bleomycin-associated NLD capsid II band is 
Figure 3. 
Association of GelStar with T3 NLD capsid II. A commercial GelStar solution was diluted to the extent 
indicated above a lane and incubated with T3 NLD capsid II. Association of GelStar with the capsid was 
determined by AGE, followed by, first, photography of fluorescence (right panel, lanes labeled NLD CII) 
and, then, staining of protein with Coomassie blue (left panel). Also analyzed was purified T3 DNA (right 
panel, lanes labeled DNA), which does not stain with Coomassie blue. The arrow indicates the direction of 
electrophoresis; the arrowheads indicate the origins.
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shown in Figure 4. Most of the free bleomycin migrated toward the cathode (not 
shown), i.e., in a direction opposite to the direction of capsid migration.
The strength of the signal in Figure 4 was weakened by the blue background 
and use of a green filter. In addition, a contaminant in the bleomycin preparation 
migrated close to the capsids, and is seen above the capsid band at the top of the left 
panel of Figure 4.
Calibration data for bleomycin, like the data for GelStar in Figure 2, were 
obtained. These data revealed that the amount of bleomycin loaded was 150–300 
molecules per capsid.
3. Discussion
In the Introduction, we outlined a strategy that is expected to work, if we can 
achieve the following objectives: (1) high (~4 h) persistence of NLD capsid II in 
blood so that the EPR effect has time to work, (2) adequate loading and sealing of 
NLD capsid II and (3) tumor-specific, controlled release (de-sealing or unloading). 
Objective #1 is likely already achieved, given the high persistence of T3 phage. That 
is to say, if one considers this strategy to be engineering based, some of the engi-
neering might already be been done by natural selection.
Concerning adequate loading, the volume of the internal cavity of NLD capsid 
II = 6.95 × 10−17 ml. For volume occupancy (FV) of 0.5 (equal to the FV of DNA 
packaged in mature phage [34]), the number of bleomycin molecules (1416 Da; 
density estimated at 1.6 g/ml as sulfate) per NLD capsid II particle is 2.4 × 104. The 
recommended dose of DDV-free bleomycin depends on the tumor, but is typically 
[39, 40] 10–20 units/m2, corresponding roughly to 10–20 mg/m2; 15 mg/m2 is 1.76 × 
1018 bleomycin molecules/m2.
To calculate the number (ND) of NLD capsid II particles needed for this dose at 
FV = 0.5, we initially assume a 25 g mouse, which on average, has 78.6 cm
2 surface 
area [41]. Then, ND is 3.6 × 10
11. A 6-liter culture yields 150–300 mouse doses of 
this size (cost ~ $1500), assuming (1) laboratory-scale production technique, (2) no 
development of procedures to increase the amount produced per bacterial cell, and 
(3) no drug-dose reduction caused by improved targeting. That is to say, if we can 
half-fill the volume of NLD capsid II, we have a viable beginning. However, thus far, 
we have filled no more than 2% of FV = 0.5, NLD capsid II volume. So, increasing 
the loading is a major objective for the future.
An apparent obstacle to achieving this goal is the nonincrease in loading as bleo-
mycin concentration increases above 2 mg/ml. At least two possible explanations 
Figure 4. 
Association of bleomycin with T3 NLD capsid II. The experiment of Figure 3 was repeated with bleomycin 
(8 mg/ml), instead of GelStar. The capsid region of the post-AGE gel is shown. The right (protein) panel has 
a single band of capsid stained with Coomassie blue. This band marks the position of the capsid-associated 
bleomycin fluorescence in the left panel. The arrow indicates direction of electrophoresis.
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exist. (1) After passing through an open gate, the bleomycin eventually causes 
the gate to close. We were hoping to close the gate by lowering temperature. (2) 
After diffusing through an open gate, the bleomycin is prevented from diffusing in 
reverse by binding to internal proteins; the internal proteins become saturated as 
the concentration of bleomycin increases. In either case, increasing the loading is a 
problem of engineering.
An advantage of using a phage DDV is that the human-design engineering 
potential is relatively high. First of all, the capsids in a T7 NLD capsid II prepara-
tion are structurally uniform enough so that symmetric cryo-EM reconstruction is 
obtained at 3.5 Å [34] and asymmetric reconstruction, at ~8 Å [36]. Assuming T3 
capsids to be comparably homogeneous, use of chemistry to improve gating should 
produce relatively uniform results.
Second, phages, in general, and phage T3 in particular, can be genetically 
manipulated, which is not possible with liposomes. Information for determining 
which nucleotides to change can be obtained from high-resolution cryo-EM struc-
ture. Structure of this type is not obtainable with liposomes.
Finally, we note that, as far as we know, the only phages tested for production 
of an NLD capsid II-like capsid are the related coliphages, T7, T3 and ϕII. All 
three of these phages produce a NLD capsid II-like capsid [42]. Other phages 
are potential sources of gated capsids, perhaps with properties even more 
DDV-favorable.
4. Materials and methods
4.1 T3 bacteriophage, capsids and DNA (nanoparticles)
We obtained bacteriophage T3 and T3 capsid II from 30°C-lysates of host, 
Escherichia coli BB/1, that had been infected by phage T3 in aerated liquid culture 
[43]. The growth medium was 2× LB medium: 2.0% Bacto tryptone, 1.0% Bacto 
yeast in 0.1 M NaCl. We initially purified both phage and capsids by centrifugation 
through a cesium chloride step gradient, followed by buoyant density centrifuga-
tion in a cesium chloride density gradient [43]. The latter fractionation separates 
capsid I from capsid II.
To separate NLD capsid II from NHD capsid II, we performed buoyant density 
centrifugation of capsid II in a Nycodenz density gradient, as previously described 
[32]. The purified NLD and NHD capsid II were dialyzed against 0.1 M NaCl, 
0.01 M Tris-Cl, pH 7.4, 0.001 M MgCl2. NLD capsid II, which formed a band near 
the top of the Nycodenz density gradient, had no detected contamination with 
NHD capsid II and vice versa, as previously seen by analytical ultracentrifugation 
[31]. Phage, NLD capsid II and NHD capsid II were dialyzed against the following 
buffer before use in the experiments described below: 0.2 M NaCl, 0.01 M Tris-Cl, 
pH 7.4, 0.001 MgCl2.
T3 DNA was obtained from purified T3 phage by phenol extraction. The DNA 
was dialyzed against and stored in 0.1 M NaCl, 0.01 M Tris-Cl, pH 7.4, 0.001 M 
EDTA. DNA concentration was obtained from optical density at 260 nm.
4.2 Fluorescent compounds: test of fluorescence emission
GelStar was obtained from Lonza (Basel, Switzerland) in solution. The company 
recommends dilution by a factor of 1:10,000 for use as a nucleic acid stain after gel 
electrophoresis. Alexa Fluor 488 succinimidyl ester was obtained from Molecular 
Probes (Eugene, OR, USA) as a powder.
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Bleomycin was obtained from Cayman Chemical Company (Ann Arbor, MI, 
USA) as a powder. The bleomycin was dissolved in the aqueous buffer indicated and 
diluted to the concentrations indicated before incubation with capsids and DNA.
Tests of fluorescence emission vs. fluorescent molecule concentration were made 
by pipetting 5 μl of diluted fluorescent molecule onto the surface of a 0.7% agarose 
gel (LE agarose, Lonza) that had been cast in a plastic Petri dish in the electropho-
resis buffer of Section 4.3. The gel was then photographed by use of the procedures 
described in Section 4.3.
4.3 Loading experiments: AGE
To test for fluorescent compound/nanoparticle association, fluorescent com-
pounds were mixed with one of the following T3 nanoparticles: NLD capsid II, 
NHD capsid II, phage, DNA. First, a 12.5 μl amount of fluorescent compound in 
0.1 M NaCl, 0.01 M sodium citrate, pH 4.0, 0.001 M MgCl2 (citrate buffer) was 
added to 4.5 μl of additional citrate buffer. Then, 8.0 μl of a nanoparticle sample 
was added and mixed (final pH, 4.1). This mixture was incubated at 45.0°C  
for 2.0 h.
To perform AGE, we added to this mixture 2.5 μl of the following solution: 60% 
sucrose (to increase the density for layering in sample wells) in the electrophoresis 
buffer below. This final mixture was layered in a well of a horizontal, submerged, 
0.7% agarose gel (LE agarose, Lonza), cast in and submerged under the following 
electrophoresis buffer: 0.05 M Tris-acetate, pH 8.4, 0.001 M MgCl2. The tempera-
ture of the gel and buffer had been pre-adjusted to 10°C in an effort to seal NLD 
capsid II and, therefore, prevent leakage of fluorescent compounds.
AGE was performed at 1.0 V/cm for 18.0 h with the gel and buffer maintained 
at 10°C by circulation through a controlled-temperature water bath. After AGE, the 
gel was soaked in 25% methanol in electrophoresis buffer for 1.5 h at room tempera-
ture, to cause leakage of fluorescent compounds from NLD capsid II and, therefore, 
to prevent auto-quenching.
Finally, the gel was photographed during illumination with a Model TM-36 
ultraviolet transilluminator (Ultra Violet Products, Inc.). The camera used was a 
Canon Power Shot G2, 4.0 Megapixels. The following Tiffin emission filters were 
used as described in Section 2: Blue, 80A #290513; Green, 11Green 1—#287305; 
Yellow, Yellow 12—#282224; Orange, Orange 16—#289750. To detect capsid 
protein, the gel was subsequently stained with Coomassie blue and photographed 
during illumination with visible light [43].
5. Conclusions
Obtaining an increase in the current tumor-specificity of anticancer drugs 
should be possible via use of a DDV that implements multiple, independent stages 
of specificity increase. T3 NLD capsid II is an example of a bio-nanoparticle that has 
undergone some of the needed DDV-bioengineering via mutation/selection in the 
environment. Other examples, not yet found, are assumed to exist and potentially 
have even more favorable characteristics.
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